Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A Polygenic Score for Type 2 Diabetes Risk Is Associated With Both the Acute and Sustained Response to Sulfonylureas

Diabetes(2020)10.2337/db20-0530Source: DataRank Database

A Polygenic Score for Type 2 Diabetes Risk Is Associated With Both the Acute and Sustained Response to Sulfonylureas is a research paper published in Diabetes (2020). On theSindex it has a DataRank of 1.4. It has been cited 38 times, with 32 citing works in its 1-hop citation network.

N/A

1.4DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access38 citations · 32 citing works in its network

Download PDF

Cite:

Data availability

Repositories this paper deposited data in (declared in PubMed).

figshare10.2337/figshare.13135517

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (16 grants)OA: bronzeTopics (26)IDs (PubMed)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 40%Citation Network 60%

Base Score Contribution

0.550

From this paper's citation signal

Citation Network Contribution

0.811

From 28 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 32 citers.

Influence of BMI-associated genetic variants and metabolic risk factors on weight loss with semaglutide: a longitudinal clinico-genomic cohort study
medRxiv20245 citations30 referencesContributes 0.060
Landscape of pharmacogenetic variants associated with non-insulin antidiabetic drugs in the Indian population
BMJ Open Diabetes Research & Care202416 citations49 referencesContributes 0.058
Genetics of Pulmonary Pressure and Right Ventricle Stress Identify Diabetes as a Causal Risk Factor
Journal of the American Heart Association202310 citations48 referencesContributes 0.050
Personalized prevention: possibilities and limitations of polygenic risk assessment
Russian Journal for Personalized Medicine20235 citations36 referencesContributes 0.050
The case for precision medicine in the prevention, diagnosis, and treatment of cardiometabolic diseases in low-income and middle-income countries
The Lancet Diabetes & Endocrinology202333 citations74 referencesContributes 0.048

Authors (7)

Łukasz Szczerbiński ORCID,Adem Y. Dawed ORCID,Varinderpal Kaur,Jennifer N. Todd ORCID,Ewan R. Pearson ORCID

Live enrichment

PubMed:33106254

National Institute of Diabetes and Digestive and Kidney Diseases

Grant: R01 DK088214

National Institute of Diabetes and Digestive and Kidney Diseases

Grant: R03 DK077675

National Institute of Diabetes and Digestive and Kidney Diseases

Grant: P30 DK036836

Grant: M01-RR-01066

Grant: 1 UL1 RR025758-04

Grant: 8UL1TR000170-05

Harvard Clinical and Translational Science Center (UL1)

National Institute of Diabetes and Digestive and Kidney Diseases

Grant: T32DK007028

Wellcome Trust

Grant: 102820/Z/13/Z

National Institutes of Health

Grant: 3T32DK007028-48S1

Training Program in Endocrinology

National Institutes of Health

Grant: 3M01RR001066-09S3

GENERAL CLINICAL RESEARCH CENTER

Wellcome Trust

Grant: unidentified

unidentified

National Institutes of Health

Grant: 2P30DK036836-36

Diabetes Research Center

Wellcome Trust

Grant: 102820

Stratified medicine in Type 2 diabetes: Insights from the study of drug response.

National Institutes of Health

Grant: 3UL1RR025758-04S1

Harvard Clinical and Translational Science Center (UL1)

National Institutes of Health

Grant: 5R03DK077675-02

Pharmacogenetics of the acute response to sulfonylurea and metformin treatment in

National Institutes of Health

Grant: 5R01DK088214-02

Study to Understand the Genetics of the Acute Response to Metformin & Glipizide

bronzeLicense: https://www.diabetesjournals.org/content/license

GREENhttps://diabetesjournals.org/diabetes/article-pdf/70/1/293/440146/db200530.pdf

publisherhttps://diabetesjournals.org/diabetes/article-pdf/70/1/293/440146/db200530.pdf

publisherhttp://diabetes.diabetesjournals.org/syndication/doi/10.2337/db20-0530

publisherhttps://journals.org/diabetes/diabetes/article-pdf/70/1/293/440146/db200530.pdf

repositoryhttps://discovery.dundee.ac.uk/en/publications/a0aee8e3-25c9-422d-8976-71e928f3747c

Fields of Study

MedicineBiology0301 basic medicine03 medical and health sciences0303 health sciences

Keywords

Blood GlucoseMaleGenotype610name=Internal MedicinePolymorphism, Single Nucleotide/dk/atira/pure/subjectarea/asjc/2700/2724HumansHypoglycemic AgentsGenetic Predisposition to DiseaseGlycated HemoglobinGenetics/Genomes/Proteomics/MetabolomicsDiabetes and MetabolismSulfonylurea CompoundsTreatment OutcomeDiabetes Mellitus, Type 2Pharmacogenetics/dk/atira/pure/subjectarea/asjc/2700/2712Femalename=EndocrinologyGenome-Wide Association Study

Sustainable Development Goals

SDG 3: 3. Good healthSDG 12: 12. Responsible consumption